AR020102A1 - Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento - Google Patents

Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento

Info

Publication number
AR020102A1
AR020102A1 ARP990103185A ARP990103185A AR020102A1 AR 020102 A1 AR020102 A1 AR 020102A1 AR P990103185 A ARP990103185 A AR P990103185A AR P990103185 A ARP990103185 A AR P990103185A AR 020102 A1 AR020102 A1 AR 020102A1
Authority
AR
Argentina
Prior art keywords
food
composition
compound
antigenic determinant
allergen
Prior art date
Application number
ARP990103185A
Other languages
English (en)
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of AR020102A1 publication Critical patent/AR020102A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717Plasma globulins, lactoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Cosmetics (AREA)

Abstract

Un compuesto para la prevencion y/o tratamiento de la alergia que comprende al menos un determinante antigénico de un alergeno que es reconocido por unacélula B o un anticuerpo secretado por una célula B de un individuo no-atopico a dicho alergeno yal menos un determinante antigénico de un antígeno diferentede dicho alergeno que dispara la activacion de las células T. Un compuesto para la prevencion y/o tratamiento de la alergia que comprende preferentemente unasecuencia de nucleotidos que codifica ambos determinantes antigénicos del compuesto de acuerdo con lo descripto, la cual puede unirse a una o más secuenciasregulatorias activas en una célula del paciente. Dicho determinante antigénico de un alergeno puede no ser reconocido por una célula T y puede ser seleccionadodel grupo integrado por los siguientes alergenos principales; Der pl y Der pll del ácaro doméstico Dermatofagoideo pteronyssinus, el antígeno principal deAspergillus fumigatus, la enterotoxina B estafilococcica (SEB) yla betalactoglubina bovina. El determinante antigénico del antígeno que dispara la activacionde las células T puede ser un epitope de célula T de antígenos del toxoide del tétano, difteria, micobacteria, influenza, o el virus del sarampion. Eldeterminante antigénico del alergeno y el determinante antigénico del antígeno son secuencias peptídicas, preferentemente unidas, por un enlace peptídico.Composicion farmacéutica, composicion cosmética, composicion en forma de bebida, alimento y/o alimentos para animales domésticos que lo comprende y uso dedicho compuesto o dicha composicion farmacéutica para la fabricacion de medicamento.
ARP990103185A 1998-07-30 1999-06-30 Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento AR020102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98870167 1998-07-30

Publications (1)

Publication Number Publication Date
AR020102A1 true AR020102A1 (es) 2002-04-10

Family

ID=8237074

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103185A AR020102A1 (es) 1998-07-30 1999-06-30 Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento

Country Status (15)

Country Link
US (1) US6602509B1 (es)
EP (1) EP1105505B1 (es)
JP (1) JP4383667B2 (es)
CN (1) CN1313903A (es)
AR (1) AR020102A1 (es)
AT (1) ATE349537T1 (es)
AU (1) AU767279B2 (es)
BR (1) BR9912702A (es)
CA (1) CA2337969C (es)
DE (1) DE69934590T2 (es)
ES (1) ES2279625T3 (es)
MX (1) MXPA01001093A (es)
PE (1) PE20000760A1 (es)
TW (1) TW589378B (es)
WO (1) WO2000006694A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637160A3 (en) 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US20040202673A1 (en) * 2003-04-08 2004-10-14 Jen-Pin Huang Constructs of branched synthetic peptide immunogens with artificial T helper cell epitopes coupled to B cell epitopes
US8543566B2 (en) 2003-09-23 2013-09-24 Salesforce.Com, Inc. System and methods of improving a multi-tenant database query using contextual knowledge about non-homogeneously distributed tenant data
US7529728B2 (en) * 2003-09-23 2009-05-05 Salesforce.Com, Inc. Query optimization in a multi-tenant database system
DE102004035337A1 (de) * 2004-07-21 2006-03-16 Merck Patent Gmbh Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität
ZA200707413B (en) 2005-03-18 2009-01-28 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
EP2476435B1 (en) * 2006-08-11 2017-12-20 Life Sciences Research Partners VZW Immunogenic peptides and their use in immune disorders
US20080109484A1 (en) * 2006-09-29 2008-05-08 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10503872B2 (en) * 2006-09-29 2019-12-10 Gearbox Llc Computational systems for biomedical data
US20080082307A1 (en) * 2006-09-29 2008-04-03 Searete Llc Computational systems for biomedical data
US20080082359A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of State Of Delaware Computational systems for biomedical data
US20080082306A1 (en) * 2006-09-29 2008-04-03 Searete Llc Computational systems for biomedical data
US10095836B2 (en) * 2006-09-29 2018-10-09 Gearbox Llc Computational systems for biomedical data
US20080082367A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082364A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082583A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10546652B2 (en) * 2006-09-29 2020-01-28 Gearbox Llc Computational systems for biomedical data
US20080082271A1 (en) * 2006-09-29 2008-04-03 Searete Llc Computational systems for biomedical data
US20080082584A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US8122073B2 (en) * 2006-09-29 2012-02-21 The Invention Science Fund I Computational systems for biomedical data
US20080091730A1 (en) * 2006-09-29 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10068303B2 (en) * 2006-09-29 2018-09-04 Gearbox Llc Computational systems for biomedical data
US7853626B2 (en) * 2006-09-29 2010-12-14 The Invention Science Fund I, Llc Computational systems for biomedical data
ITRM20060583A1 (it) * 2006-10-27 2008-04-28 Francesco Bistoni Uso della timosina alfa 1 per la preparazione di un medicamento per la prevenzione e la cura delle allergie
EP2244733B1 (en) * 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
CA2715536C (en) 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
AU2009214038B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
ES2627882T3 (es) 2008-02-14 2017-07-31 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
ES2869155T3 (es) 2010-11-25 2021-10-25 Imnate Sarl Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
EP3445390A1 (en) 2016-04-19 2019-02-27 ImCyse SA Novel immunogenic cd1d binding peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
KR100260342B1 (ko) * 1991-10-16 2000-07-01 스타세이 엘. 첸링 더마토파고이드로 부터 유래된 알레르겐의 t세포 에피토프
AU717187B2 (en) * 1994-04-14 2000-03-16 Merck Patent Gmbh Pharmaceutical peptide formulations for treatment of dust mite allergy
CA2190494C (en) * 1994-05-18 2002-05-07 Michael E. Houston Heterodimer polypeptide immunogen carrier composition and method

Also Published As

Publication number Publication date
ES2279625T3 (es) 2007-08-16
WO2000006694A2 (en) 2000-02-10
AU5142199A (en) 2000-02-21
EP1105505B1 (en) 2006-12-27
EP1105505A2 (en) 2001-06-13
MXPA01001093A (es) 2002-04-24
CN1313903A (zh) 2001-09-19
DE69934590D1 (de) 2007-02-08
WO2000006694A3 (en) 2000-03-16
DE69934590T2 (de) 2007-07-26
US6602509B1 (en) 2003-08-05
JP2002524031A (ja) 2002-08-06
BR9912702A (pt) 2001-05-08
ATE349537T1 (de) 2007-01-15
CA2337969A1 (en) 2000-02-10
PE20000760A1 (es) 2000-08-30
JP4383667B2 (ja) 2009-12-16
CA2337969C (en) 2010-06-29
TW589378B (en) 2004-06-01
AU767279B2 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
ES2190799T3 (es) Inmunogenos peptidicos para vacunacion y tratamiento de la alergia.
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
ATE392904T1 (de) Pharmazeutische zusammensetzung zur immunstimulation und zur zubereitung von impfstoffen enthaltend ein antigen, und als adjuvantien ein immunogenes oligodesoxynukleotid und ein polykationisches polypeptid
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
NO20015073L (no) Vaksiner
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
CA2224724A1 (en) Subunit vaccine against flavivirus infection
GB2255093A (en) Hiv-1 core protein fragments
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
Blanco et al. B epitope multiplicity and B/T epitope orientation influence immunogenicity of foot‐and‐mouth disease peptide vaccines
Hancock et al. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)
Moisa et al. Synthetic peptide vaccines
Salabert et al. Intradermal injection of an anti‐Langerin‐HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo
WO2007145760A3 (en) Anthrax compositions and methods of use and production
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
Gu et al. A multiple antigen peptide vaccine containing CD4+ T cell epitopes enhances humoral immunity against Trichinella spiralis infection in mice
AU2016201589B2 (en) Peptide adjuvants
Mohan et al. Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
EA200300535A1 (ru) Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
Liem et al. The protective effect of intranasal immunization with inactivated influenza virus vaccine
Romero et al. Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge